Salute e Benessere

IV Bag Market to Witness Rapid Growth, Reaching $3.4B by 2034, as Healthcare…

Request Exclusive Sample Report: IV Bag Industry Strategic Insights, https://www.futuremarketinsights.com/reports/sample/rep-gb-3580 Request Exclusive Sample Report: IV Bag Industry Strategic Insights,https://www.futuremarketinsights.com/reports/sample/rep-gb-3580 The extensive use of IV bags for delivering medications to a patient directly to the veins is another factor influencing thedemand for the IV bags market. In the backdrop of the ability of infusion therapy...
PR Newswire
26/02/2024

BBS-Bioactive Bone Substitutes Plc: Financial Statements Bulletin 2023…

BBS-Bioactive Bone Substitutes Plc, Financial Statements Bulletin 2023, 26 February 2024 at 5.45 p.m. (EET) This is a summary of BBS-Bioactive Bone Substitutes Plc's Financial Statements Bulletin for January–December 2023. The entire report is attached to this Company Announcement as a pdf file. The report is also available on BBS-Bioactive Bone Substitutes Plc's website at https://www.bbs-artebone.fi/.Preparations for commercial phase initiated JULY-DECEMBER HIGHLIGHTSIn...
Nasdaq GlobeNewswire
26/02/2024

ConcertAI's TeraRecon Launches Three New Care Suites, Life Sciences Platform…

TeraRecon's AI Partnerships for the EU market now include: TeraRecon's AI Partnerships for the EU market now include: Schedule a demo at ECR 2024 to see both TeraRecon and partner solutions live. You can also reserve time to see the new features of our flagship Intuition product, including clinical and interventional preoperative cardiovascular planning workflows, cardiac CT and MR workflows, and many more enhancements that integrate seamlessly within the clinicians' workflow to enhance...
PR Newswire
26/02/2024

Lateral Flow Assays Market Worth $16.8 billion | MarketsandMarkets™

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=167205133 Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=167205133 Browse in-depth TOC on "Lateral Flow Assays Market" 420 - Tables 59 - Figures 399 - Pages Lateral Flow Assays Market Scope: "Kits and Reagents segment is expected to witness the highest growth during the forecast period" Based on product type, the lateral flow...
PR Newswire
26/02/2024

Clinical Biomarkers Market worth $47.25 Bn by 2031 - Exclusive Report by…

According to the latest research by InsightAce Analytic, the Global Clinical Biomarkers Market is valued at US$25.02 Billion in 2023, and it is expected to reach US$ 47.25 Billion by 2031, with a CAGR of 8.54% during the forecast period of 2024-2031. According to the latest research by InsightAce Analytic, theGlobal Clinical Biomarkers Marketis valued atUS$25.02 Billion in 2023, and it is expected to reach US$ 47.25 Billionby 2031,with aCAGR of 8.54%during theforecast...
PR Newswire
26/02/2024

IVF Devices and Consumables Market to Reach $12.0 Billion, Globally, by 2032 at…

Request Sample of the Report on IVF Devices and Consumables Market Forecast - https://www.alliedmarketresearch.com/request-sample/864 Request Sample of the Report on IVF Devices and Consumables Market Forecast -https://www.alliedmarketresearch.com/request-sample/864 Prime determinants of growth Rise in rates of infertility, trend of delayed pregnancies among women, and technological advancements in IVF devices act as the key driving forces of the global IVF devices and consumables...
PR Newswire
26/02/2024

Neuroblastoma Drugs Market to Reach $1.3 Billion, Globally, by 2032 at 6.2%…

Request Sample of the Report on Neuroblastoma Drugs Market Forecast - https://www.alliedmarketresearch.com/request-sample/A172697 Request Sample of the Report on Neuroblastoma Drugs Market Forecast -https://www.alliedmarketresearch.com/request-sample/A172697 Prime determinants of growth Surge in the prevalence of neuroblastoma, growth in awareness and initiatives taken by the government for neuroblastoma and increase in R&D activities for neuroblastoma drugs are the factors...
PR Newswire
26/02/2024

Telesis Bio Announces Select Preliminary Fourth Quarter 2023 Financial Results

Telesis Bio announces Q4 and full-year 2023 select preliminary financial results, highlighting strong BioXp kit sales, expanding gross margin and reduced expense BioXp® kit revenue for the fourth quarter of 2023 is expected to exceed $1.0 million, the highest level in the history of the Company and an increase of 59.6% from the prior quarter and 25.9% compared to the same quarter last year. This increase was driven by rapid adoption of highly differentiated mRNA workflows, which grew at...
Nasdaq GlobeNewswire
26/02/2024

Cure Brain Cancer Foundation CEO Lance Kawaguchi Completes SouthPoleTrek4Cancer…

"We need to focus on brain cancer and rare cancers because it's really giving a voice to the voiceless. No one focuses on rare cancers and those are the people we need to help" – Lance Kawaguchi "We need to focus on brain cancer and rare cancers because it's really giving a voice to the voiceless. No one focuses on rare cancers and those are the people we need to help" – Lance Kawaguchi To discuss this monumental achievement, Kawaguchi was interviewed by Sky News Australia...
PR Newswire
26/02/2024

XYRA Announces Successful FDA End of Phase 2 Meeting and Agreement on Endpoints…

The Agency agrees that there is no need to perform a large long term cardiovascular (CV) outcomes study, either before or after approval. This is a testament to the improved design features introduced into a widely used and well characterized class of drugs, absence of EKG changes at therapeutics doses heretofore used and the need for monitoring with a wearable device to establish a subject on the lowest most effective dose and to discontinue if ineffective. In addition, if the drug continues to…
PR Newswire
26/02/2024

MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on…

MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody ®sonelokimab (SLK) in Hidradenitis Suppurativa (HS) Clarified path for HS Phase 3 program with study design, patient population and endpoints agreedOne dose of SLK (120mg) to be tested with a similar protocol as in Phase 2Total Phase 3 population of 800 patients to be complemented by Phase 2 population for registrationPhase 3 trial has...
Nasdaq GlobeNewswire
26/02/2024

Orion Group Financial Statement documents 2023, Corporate Governance Statement…

ORION CORPORATIONSTOCK EXCHANGE RELEASE – ANNUAL FINANCIAL REPORT 26 FEBRUARY 2024 at 14.30 EET Orion Group Financial Statement documents 2023, Corporate Governance Statement and Remuneration Report published Orion Group's Financial Statement documents for 2023 have been published. The documents are available in Finnish and English on the Company's website athttp://www.orion.fi/enand are attached to this release. The Financial Statements are published in accordance with the...
Nasdaq GlobeNewswire
26/02/2024

Mitochondrial activation in transplanted cells promotes regenerative therapy for…

A research team led by Professor Yuma Yamada of Hokkaido University's Faculty of Pharmaceutical Science has developed a technique to promote cardiac regeneration by delivering mitochondrial activators to cardiac progenitor cells. Their findings were published in the Journal of Controlled Release. A research team led by Professor Yuma Yamada ofHokkaido University'sFaculty of Pharmaceutical Science has developed a technique to promote cardiac regeneration by delivering mitochondrial...
PR Newswire
26/02/2024

Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 26 February 2024– On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2023. Under…
Nasdaq GlobeNewswire
26/02/2024

Transactions in connection with share buy-back program

Company Announcement COPENHAGEN, Denmark; February 26, 2024 – Genmab A/S (Nasdaq: GMAB).On February 14, 2024, Genmab announced the initiation of a share buy-back program to honor our commitments under our Restricted Stock Units program.The share buy-back program is expected to be completed no later than March 15, 2024, and comprises up to 190,000 shares.The following transactions were executed under the program from February 19 to February 23, 2024: No. of sharesAverage...
Nasdaq GlobeNewswire
26/02/2024

Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD…

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it has accepted an offer from investors (the “Investors”) for the sale of 10,127,132 of its ordinary shares, for an approximate value of USD 166 million, par value USD 0.01 per share (the “Shares”), at a purchase price of USD 16.41 per Share, or ISK 2,250 per share at foreign exchange rates on February 23, 2024 (the...
Nasdaq GlobeNewswire
26/02/2024

Bright Smiles, Bigger Market: KSA Dental Services Boom at 7.8% CAGR, Driven by…

Several key factors are propelling the KSA dental services market towards a brighter future: Several key factors are propelling the KSA dental services market towards a brighter future: Interested to Know More about this Report, Request a Free Sample Report Segmentation Spotlight: Ken Research provides a detailed segmentation of the market, allowing you to pinpoint your target audience effectively: Competitive Landscape: The KSA dental services market features a...
PR Newswire
26/02/2024

J INTS BIO, Phase 1/2 study of 'JIN-A02', a Novel Oral 4th Generation EGFR TKI…

The topic of the presentation is "Phase 1/2 clinical trial of JIN-A02, a 4th generation EGFR-TKI for 3rd generation EGFR-TKI resistant patients in EGFR mutated advanced/metastatic non-small cell lung cancer". The topic of the presentation is "Phase 1/2 clinical trial of JIN-A02, a 4th generation EGFR-TKI for 3rd generation EGFR-TKI resistant patients in EGFR mutated advanced/metastatic non-small cell lung cancer". 'JIN-A02', a 4th generation EGFR-TKI, selectively binds to…
PR Newswire
26/02/2024

IWA Outdoor Classics 2024 Set to Unveil World's First Tactical Thermal Imager

When asked about the key features of the XH15 compared to other thermal imagers on the market, Ryan emphasized its groundbreaking specifications. He explained, "The XH15 has the world's highest frame rate, an astonishing 60Hz." He added, "This means users can experience smooth real-time imaging even in the most dynamic environments." When asked about the key features of the XH15 compared to other thermal imagers on the market, Ryan emphasized its groundbreaking…
PR Newswire
26/02/2024

Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows…

Company announcement - No. 8 / 2024 Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosisSurvodutide has potential to become best-in-class treatment for metabolic dysfunction-associated steatohepatitis (MASH)*, after meeting its primary and key secondary endpoint following 48 weeks of treatment versus placebo in a Phase 2 trial...
Nasdaq GlobeNewswire
26/02/2024

Survodutide Phase II trial shows 83% of adults treated achieved groundbreaking…

Survodutide has potential to become best-in-class treatment for metabolic dysfunction-associated steatohepatitis (MASH)*, after meeting its primary and key secondary endpoint following 48 weeks of treatment versus placebo in a Phase II trialSurvodutide, a novel glucagon/GLP-1 receptor dual agonist, has demonstrated efficacy in people with obesity 1, and statistically significant results in MASH 2 suggest the potential to lead to clinically meaningful benefits across the cardiovascular,...
Nasdaq GlobeNewswire
26/02/2024

IBA Notice of Full Year 2023 Results and Conference Call

FY23 results meeting to take place as a hybrid event onThursday, 21 March 2024 at 3pm CET Louvain-la-Neuve, Belgium, 26 February 2024- IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, announces today that it will publish its consolidated results for the full year 2023 onThursday, 21 March 2024 at 7am CET.Conference Call Information IBA's management team will host a hybrid event, including a conference call and...
Nasdaq GlobeNewswire
26/02/2024

New England Journal of Medicine publishes Phase III data showing Xolair…

Detailed results from the NIH-sponsored Phase III OUtMATCH study showed treatment with Xolair increased the amount of peanuts, tree nuts, egg, milk and wheat that people as young as 1 year consumed without an allergic reaction The U.S. FDA recently approved Xolair as the first and only medicine for children and adults with one or more food allergies Allergic reactions can be life-threatening and it is estimated that food-related anaphylaxis results in 30,000 medical events treated in...
Nasdaq GlobeNewswire
25/02/2024

Operation Smile and Beast Philanthropy Spotlight Global Need for Access to…

"I've been so unbelievably impressed with Operation Smile," said Darren Margolias, CEO of Beast Philanthropy. "There is the surgical component and the medical component but there is a human component as well – and that is the thing that has impacted me the most." "I've been so unbelievably impressed with Operation Smile," saidDarren Margolias, CEO of Beast Philanthropy. "There is the surgical component and the medical component but there is a human component as…
PR Newswire
25/02/2024
Altri  Comunicati